Nasdaq · Biotech stocks database
IMTX (Immatics N.V.) stock: $8.62, $1.29B market cap, $406.5M cash, $883.3M EV, $1.30B fully diluted market cap. Next expected readout: Sep-27. Lead program: IMA203 (Melanoma, Cutaneous Malignant), Phase 3. Data from Fully Diluted's biotech stocks database.
| Cash | $406.5M |
|---|---|
| Debt | $0.0M |
| Net cash | $406.5M |
| Enterprise value | $883.3M |
| Basic shares | 149.6M shares |
| Fully diluted shares | 151.4M shares |
| Fully diluted market cap | $1,304.7M |
| Cash per share | $2.72 |
Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Loading IMTX daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Oct 13 - Nov 24 | IMA402 | Phase 1/2 | Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult | — |
| Feb 12 - Mar 25 | IMA203 | Phase 3 | Melanoma, Cutaneous Malignant | — |
| Jan 12 - Feb 23 | IMA203 Product | Phase 1/2 | Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult | — |
| Sep 12 - Oct 24 | IMA203 | Phase 1 | Cutaneous Melanoma; Synovial Sarcoma | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.